Marksans Pharma schedules Q2 FY27 earnings call for November 5

Board & Shareholder Meetings View source PDF Explain this filing

MARKSANS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.7%Reaction day

₹296.90

prior close

₹297.60

announcement price

After-mkt

timing

Nifty Microcap 250market+1.7%-1.0% vs market

Pharmaceuticals peers, median of 173sector+2.0%-1.3% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.3

10m

+0.8

15m

+1.6

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.7+1.7-1.0+2.0-1.3

Next day

+2.6pendingpending+2.6-0.0

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Marksans Pharma will hold an analyst and investor conference call on November 5, 2026 at 4:00 PM IST to discuss unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The presentation, audio recording and transcript will be posted on the company website.

Likely market impact

No results were disclosed. The call may provide the next operating and earnings update, and could prompt stock volatility around November 5.